Galectin Therapeutics is working to improve the lives of patients with MASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in MASH cirrhosis.
News
-
08/14/26
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update -
08/04/26
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet -
06/23/26
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (MASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More